Q-omics provides the consensus-scored OAZ3 profile across patient tissues and cancer cell-line models. OAZ3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, OAZ3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, OAZ3 RNA expression shows 18,353 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, KIRC, and ACC as cancer lineages where OAZ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OAZ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OAZ3 survival associations across molecular data types. OAZ3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OAZ3 RNA expression–survival associations across cancer types. High OAZ3 expression shows unfavorable associations in ACC, KICH, LIHC, KIRP and UCS, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for OAZ3 RNA expression.
This table summarizes OAZ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OAZ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OAZ3 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, LUAD, THCA and KIRP. The KIRC box plot shows higher OAZ3 RNA expression in tumor versus normal tissue (log2 FC = +0.409, t-test p < 0.001).
This table shows molecular features associated with OAZ3 in patient tissues and cancer cell lines. In patient samples, OAZ3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OAZ3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
